Key result
Single and dual quarter-dose BP therapies prove effective with fewer adverse events than standard-dose monotherapy.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Supports quarter-dose BP regimens as initial therapy; extends RCT evidence for efficacy with superior tolerability over standard monotherapy.
<0.001) mm Hg, respectively. In terms of adverse events, single and dual quarter-dose therapy was not significantly different from placebo and had significantly fewer adverse events compared with standard-dose monotherapy. Quarter-dose combinations could provide improvements in efficacy and tolerability of blood pressure-lowering therapy.
No takes yet. Share an insight, caveat, or question.
Bennett et al. (2017) studied this question. Single and dual quarter-dose blood pressure therapies showed significant efficacy (P<0.001) with significantly fewer adverse events than standard-dose monotherapy and similar safety to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: